The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
Abstract
CONTEXT: Stem cell therapy is rapidly developing and has generated excitement and promise as well as confusion and at times contradictory results in the lay and scientific literature. Many types of stem cells show great promise, but clinical application has lagged due to ethical concerns or difficulties in harvesting or safely and efficiently expanding sufficient quantities. In contrast, clinical indications for blood-derived (from peripheral or umbilical cord blood) and bone marrow-derived stem cells, which can be easily and safely harvested, are rapidly increasing. OBJECTIVE: To summarize new, nonmalignant, nonhematologic clinical indications for use of blood- and bone marrow-derived stem cells. EVIDENCE ACQUISITION: Search of multiple electronic databases (MEDLINE, EMBASE, Science Citation Index), US Food and Drug Administration [FDA] Drug Site, and National Institutes of Health Web site to identify studies published from January 1997 to December 2007 on use of hematopoietic stem cells (HSCs) in autoimmune, cardiac, or vascular diseases. The search was augmented by hand searching of reference lists in clinical trials, review articles, proceedings booklets, FDA reports, and contact with study authors and device and pharmaceutical companies. EVIDENCE SYNTHESIS: Of 926 reports identified, 323 were examined for feasibility and toxicity, including those with small numbers of patients, interim or substudy reports, and reports on multiple diseases, treatment of relapse, toxicity, mechanism of action, or stem cell mobilization. Another 69 were evaluated for outcomes. For autoimmune diseases, 26 reports representing 854 patients reported treatment-related mortality of less than 1% (2/220 patients) for nonmyeloablative, less than 2% (3/197) for dose-reduced myeloablative, and 13% (13/100) for intense myeloablative regimens, ie, those including total body irradiation or high-dose busulfan. While all trials performed during the inflammatory stage of autoimmune disease suggested that transplantation of HSCs may have a potent disease-remitting effect, remission duration remains unclear, and no randomized trials have been published. For reports involving cardiovascular diseases, including 17 reports involving 1002 patients with acute myocardial infarction, 16 involving 493 patients with chronic coronary artery disease, and 3 meta-analyses, the evidence suggests that stem cell transplantation performed in patients with coronary artery disease may contribute to modest improvement in cardiac function. CONCLUSIONS: Stem cells harvested from blood or marrow, whether administered as purified HSCs or mesenchymal stem cells or as an unmanipulated or unpurified product can, under appropriate conditions in select patients, provide disease-ameliorating effects in some autoimmune diseases and cardiovascular disorders. Clinical trials are needed to determine the most appropriate cell type, dose, method, timing of delivery, and adverse effects of adult HSCs for these and other nonmalignant disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724
Assmus, B., Schächinger, V., Teupe, C., Britten, M., Lehmann, R., Döbert, N., Grünwald, F., Aicher, A., Urbich, C., Martin, H., et al. (2002) · Circulation · doi:10.1161/01.cir.0000043246.74879.cd · Cited by 2,201
Wollert, K. C., Meyer, G. P., Lotz, J., Ringes Lichtenberg, S., Lippolt, P., Breidenbach, C., Fichtner, S., Korte, T., Hornig, B., Messinger, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16626-9 · Cited by 2,191
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
Schächinger, V., Erbs, S., Elsässer, A., Haberbosch, W., Hambrecht, R., Hölschermann, H., Yu, J., Corti, R., Mathey, D. G., Hamm, C. W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060186 · Cited by 1,890
Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., Amano, K., Kishimoto, Y., Yoshimoto, K., Akashi, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09670-8 · Cited by 1,734
Intracoronary Injection of Mononuclear Bone Marrow Cells in Acute Myocardial Infarction
Lunde, K., Solheim, S., Aakhus, S., Arnesen, H., Abdelnoor, M., Egeland, T., Endresen, K., Ilebekk, A., Mangschau, A., Fjeld, J. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055706 · Cited by 1,310
Janssens, S., Dubois, C., Bogaert, J., Theunissen, K., Deroose, C., Desmet, W., Kalantzi, M., Herbots, L., Sinnaeve, P., Dens, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67861-0 · Cited by 1,294
Perin, E. C., Dohmann, H. F. R., Borojevic, R., Silva, S. A., Sousa, A. L. S., Mesquita, C. T., Rossi, M. I. D., Carvalho, A. C., Dutra, H. S., Dohmann, H. J. F., et al. (2003) · Circulation · doi:10.1161/01.cir.0000070596.30552.8b · Cited by 1,290
Cited by
Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2
Burchfield, J. S., Xie, M., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001878 · Cited by 766
Assessing Identity, Phenotype, and Fate of Endothelial Progenitor Cells
Hirschi, K. K., Ingram, D. A., & Yoder, M. C. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.155960 · Cited by 746
Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Quevedo, H. C., Hatzistergos, K. E., Oskouei, B. N., Feigenbaum, G. S., Rodriguez, J. E., Valdes, D., Pattany, P. M., Zambrano, J. P., Hu, Q., McNiece, I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903201106 · Cited by 586
Burt, R. K., Shah, S. J., Dill, K., Grant, T., Gheorghiade, M., Schroeder, J., Craig, R., Hirano, I., Marshall, K., Ruderman, E., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60982-3 · Cited by 578
Self-citation
Metadata
- Authors
- Burt, R. K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-02-27
- Volume
- 299
- Issue
- 8
- Pages
- 925
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2116763826
- Cited by
- 354
- References
- 71
- FWCI
- 30.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases. https://app.cochat.ai/papers/10.1001/jama.299.8.925
- The paper
- Burt, R. K. (2008). Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases. JAMA. https://doi.org/10.1001/jama.299.8.925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.